Johnson & Johnson (NYSE:JNJ) Forecasted to Earn Q3 2024 Earnings of $2.74 Per Share

Johnson & Johnson (NYSE:JNJFree Report) – Investment analysts at Zacks Research boosted their Q3 2024 earnings estimates for Johnson & Johnson in a report issued on Friday, February 9th. Zacks Research analyst K. Shah now expects that the company will post earnings of $2.74 per share for the quarter, up from their previous forecast of $2.72. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.65 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q4 2024 earnings at $2.53 EPS, FY2024 earnings at $10.61 EPS, Q1 2025 earnings at $2.62 EPS, Q2 2025 earnings at $2.75 EPS, Q3 2025 earnings at $2.72 EPS, Q4 2025 earnings at $2.75 EPS, FY2025 earnings at $10.84 EPS and FY2026 earnings at $11.33 EPS.

JNJ has been the topic of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $167.00 to $180.00 in a research report on Friday, December 1st. upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Tuesday, February 6th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $176.14.

Read Our Latest Report on JNJ

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $157.87 on Monday. The stock’s 50-day simple moving average is $158.18 and its two-hundred day simple moving average is $158.62. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $380.04 billion, a P/E ratio of 11.43, a P/E/G ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. During the same quarter last year, the company earned $2.35 earnings per share.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be issued a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 3.02%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Hibernia Wealth Partners LLC bought a new stake in Johnson & Johnson in the third quarter valued at about $27,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $37,000. Tower View Wealth Management LLC lifted its holdings in Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after purchasing an additional 165 shares during the last quarter. Keener Financial Planning LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth approximately $40,000. Finally, WFA Asset Management Corp lifted its holdings in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares during the period. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.